HomeCompareVTA vs MRK

VTA vs MRK: Dividend Comparison 2026

VTA yields 122.59% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VTA wins by $9.36M in total portfolio value
10 years
VTA
VTA
● Live price
122.59%
Share price
$11.45
Annual div
$14.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9.42M
Annual income
$3,615,814.51
Full VTA calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — VTA vs MRK

📍 VTA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVTAMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VTA + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VTA pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VTA
Annual income on $10K today (after 15% tax)
$10,419.74/yr
After 10yr DRIP, annual income (after tax)
$3,073,442.33/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, VTA beats the other by $3,065,113.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VTA + MRK for your $10,000?

VTA: 50%MRK: 50%
100% MRK50/50100% VTA
Portfolio after 10yr
$4.74M
Annual income
$1,812,806.33/yr
Blended yield
38.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

VTA
Analyst Ratings
1
Buy
Consensus: Buy
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VTA buys
0
MRK buys
0
No recent congressional trades found for VTA or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVTAMRK
Forward yield122.59%2.76%
Annual dividend / share$14.04$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$9.42M$56.8K
Annual income after 10y$3,615,814.51$9,798.13
Total dividends collected$8.58M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: VTA vs MRK ($10,000, DRIP)

YearVTA PortfolioVTA Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$22,959$12,258.52$11,206$366.19+$11.8KVTA
2$50,868$26,302.55$12,650$502.35+$38.2KVTA
3$108,894$54,464.86$14,407$694.19+$94.5KVTA
4$225,482$108,965.66$16,585$967.82+$208.9KVTA
5$452,136$210,869.94$19,342$1,363.89+$432.8KVTA
6$878,959$395,173.48$22,913$1,947.19+$856.0KVTA
7$1,658,451$717,965.66$27,662$2,823.89+$1.63MVTA
8$3,040,603$1,266,059.72$34,159$4,173.35+$3.01MVTA
9$5,422,784$2,169,338.58$43,337$6,308.80+$5.38MVTA
10$9,418,193$3,615,814.51$56,776$9,798.13+$9.36MVTA

VTA vs MRK: Complete Analysis 2026

VTAStock

Invesco Dynamic Credit Opportunities Fund is a diversified closed-end management investment company. The Fund's investment objective is to seek a high level of current income, with a secondary objective of capital appreciation. The Fund invests primarily in a portfolio of interests in floating or variable senior loans to corporations, partnerships and other entities, which operate in a range of industries and geographic regions. The Fund invests in various sectors, which include business equipment and services; electronics and electrical; retailers (except food and drug); telecommunications; utilities; food products; healthcare; leisure goods, activities and movies; lodging and casinos; oil and gas; containers and glass products; structured products; cable and satellite television, and financial intermediaries. It may invest in senior loans to borrowers that are organized or located in countries other than the United States. The Fund's investment advisor is Invesco Advisers, Inc.

Full VTA Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this VTA vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VTA vs SCHDVTA vs JEPIVTA vs OVTA vs KOVTA vs MAINVTA vs JNJVTA vs ABBVVTA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.